ArticleContemporary clinical trials2025
Rationale and design of the IMProving Adherence to medications for breast Cancer and cardiovascular disease equiTably (IMPACT) randomized clinical trial.
Article in Contemporary clinical trials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05496829 (IMPACT Trial), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IMPACT Trial: Intervention to iMProve AdherenCe Equitably
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundCardiovascular disease (CVD) is a leading cause of mortality in patients with early-stage breast cancer (BC), many of whom are prescribed endocrine therapy (ET) to prevent BC recurrence. Yet, nonadherence to ET and CVD medications is common among BC survivors, particularly in underserved populations at high risk for adverse outcomes. Little is known about how to equitably improve medication adherence for multiple chronic conditions.
methodsThe IMProving Adherence to Medications for Breast Cancer and Cardiovascular Disease EquiTably (IMPACT) trial is an investigator-initiated, single-center (multisite), two-arm randomized trial. Patients in BC clinics are screened for nonadherence to ET and CVD medications (antihypertensive or statin) using prescription fill data and a self-report questionnaire. A total of 300 patients with stage I-III BC who screen positive for nonadherence will be randomized to receive an equity-focused multicomponent medication adherence intervention versus minimally-enhanced usual care. The intervention includes nurse-led medication reconciliation, a one-time optional training in the use of the electronic patient portal and a smartphone adherence-focused application, and two structured pharmacist counseling sessions tailored to patients' adherence barriers. The control group receives medication reconciliation only. The primary outcome is adherence to ET and CVD medications by self-report and pharmacy fill data at 28 weeks. Key secondary outcomes include medication adherence at 52 weeks, adherence to individual medication classes, CVD risk factor control (BP, LDL), and patient-reported outcomes. DISCUSSION: The IMPACT trial will determine the effect of a multicomponent medication adherence intervention that targets nonadherent patients and is tailored to individual-level reasons for nonadherence.
trial registrationClinicalTrials.gov (NCT05496829).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.